Fulgent: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Fulgent (NASDAQ:FLGT) announced full-year 2026 revenue guidance of $330 million to $340 million. Cash reserves reached $652.4 million after the receipt of a federal tax refund, providing financial flexibility as laboratory collections recover. Three things management said stand out. Management transitioned its revenue cycle management (RCM), billing, and collection software to increase operational efficiency across newly acquired laboratories. Customization delays temporarily depressed collection rates in prior quarters, but operational adjustments delivered immediate sequential margin gains. Laboratory automation relies on artificial intelligence (AI, software designed to automate visual pattern recognition) to process tissue samples with high precision. Fulgent has scaled processing volume while reducing software analysis errors, thereby driving diagnostic speed and creating operational efficiency as test volumes grow. Continue reading